Zevra Therapeutics (NASDAQ:ZVRA) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research report sent to investors on Friday, Benzinga reports. The firm currently has a $20.00 price target on the stock.

Zevra Therapeutics Trading Up 6.1 %

ZVRA opened at $5.38 on Friday. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.19. The company has a market cap of $182.56 million, a price-to-earnings ratio of -5.72 and a beta of 2.22. Zevra Therapeutics has a 12 month low of $4.05 and a 12 month high of $6.92. The stock has a fifty day moving average of $4.97.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its earnings results on Monday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.24. Zevra Therapeutics had a negative return on equity of 40.67% and a negative net margin of 196.40%. The company had revenue of $8.47 million for the quarter, compared to analyst estimates of $2.90 million. On average, equities research analysts forecast that Zevra Therapeutics will post -1.29 EPS for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.